|
1
|
Subudhi SK: New approaches to
immunotherapy for metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol. 17:283–286. 2019.PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He BM, Chen R, Sun TQ, Yang Y, Zhang CL,
Ren SC, Gao X and Sun YH: Prostate cancer risk prediction models in
Eastern Asian populations: Current status, racial difference, and
future directions. Asian J Androl. 22:158–161. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koo K and Hyams ES: Assessment of men's
risk thresholds to proceed with prostate biopsy for the early
detection of prostate cancer. Int Urol Nephrol. 51:1297–1302. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dalla Via J, Daly RM, Owen PJ, Mundell NL,
Rantalainen T and Fraser SF: Bone mineral density, structure,
distribution and strength in men with prostate cancer treated with
androgen deprivation therapy. Bone. 127:367–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grun LK, Teixeira NDR Jr, Mengden LV, de
Bastiani MA, Parisi MM, Bortolin R, Lavandoski P, Pierdoná V, Alves
LB, Moreira JCF, et al: TRF1 as a major contributor for telomeres'
shortening in the context of obesity. Free Radic Biol Med.
129:286–295. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu J, Sun L, Wang LM and Jiang SJ:
Analysis of the nuclear localization signal of TRF1 in non-small
cell lung cancer. Biol Res. 42:217–222. 2009.PubMed/NCBI
|
|
8
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi RU, Prieto-Vila M, Kohama I and
Ochiya T: Development of miRNA-based therapeutic approaches for
cancer patients. Cancer Sci. 110:1140–1147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu G and Li B: Role of miRNA in
transformation from normal tissue to colorectal adenoma and cancer.
J Cancer Res Ther. 15:278–285. 2019.PubMed/NCBI
|
|
11
|
Vos PD, Leedman PJ, Filipovska A and
Rackham O: Modulation of miRNA function by natural and synthetic
RNA-binding proteins in cancer. Cell Mol Life Sci. 76:3745–3752.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kogure A, Kosaka N and Ochiya T:
Cross-talk between cancer cells and their neighbors via miRNA in
extracellular vesicles: An emerging player in cancer metastasis. J
Biomed Sci. 26:72019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang M, Jiang S, Zhou L, Yu F, Ding H, Li
P, Zhou M and Wang K: Potential Mechanisms of Action of Curcumin
for Cancer Prevention: Focus on Cellular Signaling Pathways and
miRNAs. Int J Biol Sci. 15:1200–1214. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu Z, Wang Z, Li F, Yang J and Tang L: miR
138 modulates prostate cancer cell invasion and migration via Wnt/β
catenin pathway. Mol Med Rep. 17:3140–3145. 2018.PubMed/NCBI
|
|
15
|
Li L, Tang P, Li S, Qin X, Yang H, Wu C
and Liu Y: Notch signaling pathway networks in cancer metastasis: A
new target for cancer therapy. Med Oncol. 34:1802017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen CH, Li SX, Xiang LX, Mu HQ, Wang SB
and Yu KY: HIF-1α induces immune escape of prostate cancer by
regulating NCR1/NKp46 signaling through miR-224. Biochem Biophys
Res Commun. 503:228–234. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dinami R, Ercolani C, Petti E, Piazza S,
Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, et
al: miR-155 drives telomere fragility in human breast cancer by
targeting TRF1. Cancer Res. 74:4145–4156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk - database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A Portal for Facilitating Tumor Subgroup Gene
Expression and Survival Analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA; Grading Committee, : The 2014
International Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma: Definition of
Grading Patterns and Proposal for a New Grading System. Am J Surg
Pathol. 40:244–252. 2016.PubMed/NCBI
|
|
22
|
Blanker MH and Bangma CH: Presence of
prostate cancer, but absence of active treatment. Ned Tijdschr
Geneeskd. 163:D36982019.(In Dutch). PubMed/NCBI
|
|
23
|
Wang L, Tu Z, Liu C, Liu H, Kaldis P, Chen
Z and Li W: Dual roles of TRF1 in tethering telomeres to the
nuclear envelope and protecting them from fusion during meiosis.
Cell Death Differ. 25:1174–1188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee YW, Arora R, Wischnewski H and Azzalin
CM: TRF1 participates in chromosome end protection by averting
TRF2-dependent telomeric R loops. Nat Struct Mol Biol. 25:147–153.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bejarano L, Schuhmacher AJ, Méndez M,
Megías D, Blanco-Aparicio C, Martínez S, Pastor J, Squatrito M and
Blasco MA: Inhibition of TRF1 Telomere Protein Impairs Tumor
Initiation and Progression in Glioblastoma Mouse Models and
Patient-Derived Xenografts. Cancer Cell. 32:590–607.e4. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Q, Wang G, Lyu Y, Bai M, Jiapaer Z,
Jia W, Han T, Weng R, Yang Y, Yu Y, et al: The miR-590/Acvr2a/Terf1
Axis Regulates Telomere Elongation and Pluripotency of Mouse iPSCs.
Stem Cell Reports. 11:88–101. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chan FL, Vinod B, Novy K, Schittenhelm RB,
Huang C, Udugama M, Nunez-Iglesias J, Lin JI, Hii L, Chan J, et al:
Aurora Kinase B, a novel regulator of TERF1 binding and telomeric
integrity. Nucleic Acids Res. 45:12340–12353. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bryan TM, Englezou A, Dalla-Pozza L,
Dunham MA and Reddel RR: Evidence for an alternative mechanism for
maintaining telomere length in human tumors and tumor-derived cell
lines. Nat Med. 3:1271–1274. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai C, Zhi Y, Wang K, Zhang P, Ji Z, Xie C
and Sun F: CircHIPK3 overexpression accelerates the proliferation
and invasion of prostate cancer cells through regulating
miRNA-338-3p. OncoTargets Ther. 12:3363–3372. 2019. View Article : Google Scholar
|
|
31
|
Zhu M, Zheng Z, Huang J, Ma X, Huang C, Wu
R, Li X, Liang Z, Deng F, Wu J, et al: Modulation of miR-34a in
curcumin-induced antiproliferation of prostate cancer cells. J Cell
Biochem. 120:15616–15624. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li N, Zhang LY, Qiao YH and Song RJ: Long
noncoding RNA LINC00662 functions as miRNA sponge to promote the
prostate cancer tumorigenesis through targeting miR-34a. Eur Rev
Med Pharmacol Sci. 23:3688–3698. 2019.PubMed/NCBI
|
|
33
|
Leung YK, Chan QK, Ng CF, Ma FM, Tse HM,
To KF, Maranchie J, Ho SM and Lau KM: Correction: Hsa-miRNA-765 as
a Key Mediator for Inhibiting Growth, Migration and Invasion in
Fulvestrant-Treated Prostate Cancer. PLoS One. 14:e02141842019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Witten LW, Cheng CJ and Slack FJ: miR-155
drives oncogenesis by promoting and cooperating with mutations in
the c-Kit oncogene. Oncogene. 38:2151–2161. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Witten L and Slack FJ: miR-155 as a novel
clinical target for hematological malignancies. Carcinogenesis.
41:2–7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jurkovicova D, Magyerkova M, Kulcsar L,
Krivjanska M, Krivjansky V, Gibadulinova A, Oveckova I and Chovanec
M: miR-155 as a diagnostic and prognostic marker in hematological
and solid malignancies. Neoplasma. 61:241–251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Zhao H and Zhang L:
Identification of the tumor suppressive function of circular RNA
FOXO3 in non small cell lung cancer through sponging miR-155. Mol
Med Rep. 17:7692–7700. 2018.PubMed/NCBI
|
|
38
|
Yang YP, Nguyen PNN, Ma HI, Ho WJ, Chen
YW, Chien Y, Yarmishyn AA, Huang PI, Lo WL, Wang CY, et al: Tumor
Mesenchymal Stromal Cells Regulate Cell Migration of Atypical
Teratoid Rhabdoid Tumor through Exosome-Mediated miR155/SMARCA4
Pathway. Cancers (Basel). 11:E7202019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yadav S, Singh N, Shah PP, Rowbotham DA,
Malik D, Srivastav A, Shankar J, Lam WL, Lockwood WW and Beverly
LJ: MIR155 Regulation of Ubiquilin1 and Ubiquilin2: Implications in
Cellular Protection and Tumorigenesis. Neoplasia. 19:321–332. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Yan L, Zhang L, Xu H, Chen T, Li
Y, Wang H, Chen S, Wang W, Chen C, et al: NT21MP negatively
regulates paclitaxel-resistant cells by targeting miR 155 3p and
miR 155-5p via the CXCR4 pathway in breast cancer. Int J Oncol.
53:1043–1054. 2018.PubMed/NCBI
|
|
41
|
Deep G, Kumar R, Nambiar DK, Jain AK,
Ramteke AM, Serkova NJ, Agarwal C and Agarwal R: Silibinin inhibits
hypoxia-induced HIF-1α-mediated signaling, angiogenesis and
lipogenesis in prostate cancer cells: In vitro evidence and in vivo
functional imaging and metabolomics. Mol Carcinog. 56:833–848.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hasan D, Gamen E, Abu Tarboush N, Ismail
Y, Pak O and Azab B: PKM2 and HIF-1α regulation in prostate cancer
cell lines. PLoS One. 13:e02037452018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen B, Zhang M, Xing D and Feng Y:
Atorvastatin enhances radiosensitivity in hypoxia-induced prostate
cancer cells related with HIF-1α inhibition. Biosci Rep.
37:BSR201703402017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mohamed AA, Tan SH, Xavier CP, Katta S,
Huang W, Ravindranath L, Jamal M, Li H, Srivastava M, Srivatsan ES,
et al: Synergistic activity with NOTCH inhibition and androgen
ablation in ERG-positive prostate cancer cells. Mol Cancer Res.
15:1308–1317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Deng G, Ma L, Meng Q, Ju X, Jiang K, Jiang
P and Yu Z: Notch signaling in the prostate: Critical roles during
development and in the hallmarks of prostate cancer biology. J
Cancer Res Clin Oncol. 142:531–547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu
Q, Zhou Q and Zhang J: Targeting the Notch signaling pathway in
cancer therapeutics. Thorac Cancer. 5:473–486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kita Y, Goto T, Akamatsu S, Yamasaki T,
Inoue T, Ogawa O and Kobayashi T: Castration-resistant prostate
cancer refractory to second-generation androgen receptor
axis-targeted agents: Opportunities and challenges. Cancers
(Basel). 10:3452018. View Article : Google Scholar
|
|
48
|
Domingo-Domenech J, Vidal SJ,
Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco
R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J,
et al: Suppression of acquired docetaxel resistance in prostate
cancer through depletion of notch- and hedgehog-dependent
tumor-initiating cells. Cancer Cell. 22:373–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
